SCHEMBL1933246

SCHEMBL1933246

NC(=O)c1nc2c(C(N)=O)cccc2[nH]1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 18/20 0.69
PARP2 Q9UGN5 3/20 0.61
PKN1 Q16512 2/20 0.60
PKN2 Q16513 2/20 0.60
PLK4 O00444 1/20 0.60
MAPK13 O15264 1/20 0.60
DYRK3 O43781 1/20 0.60
ROCK2 O75116 1/20 0.60
RPS6KA5 O75582 1/20 0.60
PRKD3 O94806 1/20 0.60
MAP4K4 O95819 1/20 0.60
CHEK2 O96017 1/20 0.60
PIM1 P11309 1/20 0.60
PHKG2 P15735 1/20 0.60
PRKACA P17612 1/20 0.60
RPS6KB1 P23443 1/20 0.60
CSNK1D P48730 1/20 0.60
CLK2 P49760 1/20 0.60
GSK3A P49840 1/20 0.60
PRKX P51817 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127145 0.85 PKN1 (0.59) PARP1PARP2PKN1PKN2
SCHEMBL3726213 0.83 CHEK1 (0.49) PARP1PARP2PKN1PKN2PLK4
SCHEMBL16497016 0.83 PARP1 (0.69) PARP1PARP2PKN1PKN2PLK4
SCHEMBL6842051 0.83 PARP1 (0.69) PARP1PARP2PKN1PKN2PLK4
SCHEMBL4629094 0.83 PARP1 (0.47) PARP1PARP2PKN1PKN2PLK4
SCHEMBL871829 0.81 PARP1 (1.00) PARP1PARP2PKN1PKN2PLK4
SCHEMBL20479886 0.81 PARP1 (0.46) PARP1PARP2PKN1PKN2PLK4
SCHEMBL3137529 0.81 HRH4 (0.58) PARP1
SCHEMBL25022851 0.79 PARP1 (0.63) PARP1PARP2PKN1PKN2PLK4
SCHEMBL20479692 0.79 PARP1 (0.51) PARP1PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778675-A1 CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF Cylene Pharmaceuticals, Inc. (US) 2007-05-02 EP claimed
WO-2006015150-A1 CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF CYLENE PHARMACEUTICALS (US) 2006-02-09 WO claimed
EP-2506837-B1 SPIDER SILK PARTICLES FOR CONTROLLED AND SUSTAINED DELIVERY OF COMPOUNDS AMSILK GMBH (DE) 2020-07-01 EP disclosed
EP-2654418-B1 AGRICULTURAL COMPOSITION COMPRISING PH SENSITIVE AGRICULTURAL CHEMICALS AND ORGANIC PH BUFFER NUTRIAG LTD (CA) 2017-08-23 EP disclosed
US-9277747-B2 Agricultural composition comprising pH sensitive agricultural chemicals and organic pH buffer NUTRIAG LTD. (CA) 2016-03-08 US disclosed
US-9233067-B2 Silk particles for controlled and sustained delivery of compounds AMSILK GMBH (DE) 2016-01-12 US disclosed
EP-2654418-A1 AGRICULTURAL COMPOSITION COMPRISING PH SENSITIVE AGRICULTURAL CHEMICALS AND ORGANIC PH BUFFER Nutriag Ltd. (CA) 2013-10-30 EP disclosed
US-20130109762-A1 SILK PARTICLES FOR CONTROLLED AND SUSTAINED DELIVERY OF COMPOUNDS AMSILK GMBH (DE) 2013-05-02 US disclosed
EP-2506837-A2 SPIDER SILK PARTICLES FOR CONTROLLED AND SUSTAINED DELIVERY OF COMPOUNDS Amsilk GmbH (DE) 2012-10-10 EP disclosed
WO-2012083453-A1 AGRICULTURAL COMPOSITION COMPRISING PH SENSITIVE AGRICULTURAL CHEMICALS AND ORGANIC PH BUFFER NUTRIAG LTD. (CA) 2012-06-28 WO disclosed
US-20120157317-A1 AGRICULTURAL COMPOSITION COMPRISING PH SENSITIVE AGRICULTURAL CHEMICALS AND ORGANIC PH BUFFER NUTRIAG LTD (CA) 2012-06-21 US disclosed
WO-2006015150-A1 CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF CYLENE PHARMACEUTICALS (US) 2006-02-09 WO disclosed
US-20040214821-A1 Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents SIRCAR JAGADISH C (US) 2004-10-28 US disclosed
US-6759425-B2 USEFUL IN THE TREATMENT OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IGE IS PATHOGENIC; ALSO ARE USEFUL AS ANTICANCER AGENTS. AVANIR PHARMACEUTICALS 2004-07-06 US disclosed
EP-1368028-A1 BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION AVANIR PHARMACEUTICALS (US) 2003-12-10 EP disclosed
WO-2002072090-A1 BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION AVANIR PHARMACEUTICALS (US) 2002-09-19 WO disclosed
US-20020132808-A1 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation AVANIR PHARMACEUTICALS 2002-09-19 US disclosed
US-5514639-A COLORING GOUWS & SCHEEPERS (PROPRIETARY) LIMITED (ZA) 1996-05-07 US disclosed
US-5278132-A PH color indicator for acidity water GOUWS & SCHEEPERS (PROPIETARY) LTD. (ZA) 1994-01-11 US disclosed
US-5216003-A Antihypoxic, antiischemic agents G. D. SEARLE & CO. (US) 1993-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214821-A1 Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents FCER2, CMA1, FCGR1A PARP1 1241/4885PARP2 1308/4885PKN1 2256/4885
US-20020132808-A1 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation MKI67, CMA1, CCNI PARP1 762/4885PARP2 916/4885PKN1 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.